CAS: 22059-60-5; 4-(Diisopropylamino)-2-Phenyl-2-(Pyridin-2-yl)Butanamide Phosphate

该化合物是一种主要用作治疗某类非正常心跳的抗体剂的药物化合物,是IA类抗呼吸系统的成员,通过阻塞心脏组织中的钠渠道,稳定心膜,减少易感性能,该物质似乎是白色的,白色的晶状粉,在水中溶解,有利于临床环境中的治疗.磷酸分解磷酸盐的半衰期相对较长,可以比其他抗呼吸系统药物少用.其药理效应包括负的异体和色体外作用,可能导致心率下降和萎缩性.然而,它也可能造成副作用,如口干,尿液保留和由于抗胆碱性特性而模糊的视力.与任何药物一样,应仔细监测其使用情况,特别是在有前期症状的病人或可能与影响发生相互作用的其他药物患者中.

结构式图片

欧盟法规

ECHA物质ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-4469701-A
    优先权日:1983-06-23
    标题 :Pyrrolid-3-en-2-ones and pharmaceutical methods of use thereof
    发明人:DEBAUN JACK R; PALLOS FERENC M; MATSUMOTO KENT E; ROSS JOHN H
    权利人:STAUFFER CHEMICAL CO
    摘要:Novel compounds having the structural formula ##STR1## wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, alkyl, haloalkyl, thioalkyl, thiohaloalkyl, alkoxy, cyano and nitro are provided. The compounds have various pharmacological effects, including cardiotropic, hypoglycemic, hypocholesterolemic and/or antiulcerative effects in mammals. Methods of achieving these various pharmacological effects in mammals by administering the compounds thereto are provided. Pharmaceutical compositions and formulations including the compounds are provided along with methods of synthesis of the novel compounds.

    专利号:US-9550000-B2
    优先权日:2011-09-09
    标题 :Compositions, methods, and systems for the synthesis and use of imaging agents
    发明人:ROBINSON SIMON P; YU MING
    权利人:ROBINSON SIMON P; YU MING; LANTHEUS MEDICAL IMAGING INC
    摘要:The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

    专利号:US-10814013-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A1
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-B2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S. Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate. Europace. 2006 May;8(5):345-8. Japanese.
    12: Katoh T, Sasaki Y, Tsuda T. [Effects of disopyramide phosphate in repetitive paroxysmal ventricular tachycardia]. Kokyu To Junkan. 1982 Sep;30(9):959-64. Japanese. Japanese.
    18: Sinatra ST, Landry AB Jr, Galle JS, Amato J. Cardiogenic shock associated with disopyramide phosphate. JAMA. 1980 Mar 21;243(11):1132.

    合成参考文献


    摘要:Nippon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine., 72(1177), 1983 []
    摘要:Journal of Analytical Toxicology., 6(255), 1982 []
    摘要:Medical Journal of Australia., 2(335), 1978
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知